Blair William & Co. IL Decreases Stake in Johnson & Johnson (NYSE:JNJ)

Key Points

• Blair William & Co. IL decreased its stake in Johnson & Johnson by 4.6%, owning 957,661 shares valued at approximately $158.8 million after selling 46,199 shares in the first quarter.
• Several institutional investors have increased their positions in Johnson & Johnson, with notable increases by Northern Trust Corp and Bank of New York Mellon Corp, resulting in a significant 69.55% of the stock being owned by hedge funds and institutional investors.
• Johnson & Johnson reported a quarterly revenue of $23.74 billion, exceeding analyst estimates, alongside declaring a quarterly dividend of $1.30 per share with a dividend yield of 3.1%.

Blair William & Co. IL reduced its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 4.6% during the 1st quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 957,661 shares of the company's stock after selling 46,199 shares during the period. Blair William & Co. IL's holdings in Johnson & Johnson were worth $158,819,000 at the end of the most recent reporting period.

Several other institutional investors also recently made changes to their positions in the stock. Northern Trust Corp boosted its position in shares of Johnson & Johnson by 12.3% in the 4th quarter. Northern Trust Corp now owns 30,813,175 shares of the company's stock worth $4,456,201,000 after buying an additional 3,363,235 shares in the last quarter. Bank of New York Mellon Corp increased its stake in shares of Johnson & Johnson by 26.4% during the 1st quarter. Bank of New York Mellon Corp now owns 23,182,464 shares of the company's stock valued at $3,844,580,000 after acquiring an additional 4,842,582 shares during the last quarter. Invesco Ltd. increased its stake in shares of Johnson & Johnson by 6.5% during the 4th quarter. Invesco Ltd. now owns 19,126,079 shares of the company's stock valued at $2,766,014,000 after acquiring an additional 1,171,975 shares during the last quarter. Massachusetts Financial Services Co. MA increased its stake in shares of Johnson & Johnson by 2.5% during the 1st quarter. Massachusetts Financial Services Co. MA now owns 18,282,410 shares of the company's stock valued at $3,031,955,000 after acquiring an additional 448,666 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its position in Johnson & Johnson by 4.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 14,773,493 shares of the company's stock worth $2,136,390,000 after purchasing an additional 636,430 shares in the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

JNJ has been the subject of several recent research reports. Erste Group Bank raised shares of Johnson & Johnson from a "hold" rating to a "buy" rating in a research report on Wednesday, July 23rd. Royal Bank Of Canada increased their target price on Johnson & Johnson from $181.00 to $185.00 and gave the company an "outperform" rating in a research note on Thursday, July 17th. UBS Group raised their price objective on Johnson & Johnson from $180.00 to $190.00 and gave the stock a "buy" rating in a research note on Thursday, July 17th. Sanford C. Bernstein restated a "market perform" rating on shares of Johnson & Johnson in a research note on Wednesday, April 16th. Finally, Raymond James Financial cut their target price on Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating on the stock in a research note on Monday, April 14th. Nine investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $174.50.

Johnson & Johnson Price Performance

NYSE:JNJ opened at $167.33 on Friday. The business's 50-day moving average price is $157.46 and its 200 day moving average price is $156.68. The firm has a market cap of $402.99 billion, a P/E ratio of 17.90, a PEG ratio of 2.13 and a beta of 0.41. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $169.99. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, topping analysts' consensus estimates of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%. The firm had revenue of $23.74 billion during the quarter, compared to analyst estimates of $22.85 billion. During the same period last year, the company posted $2.82 EPS. The business's quarterly revenue was up 5.8% compared to the same quarter last year. As a group, sell-side analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be issued a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 3.1%. The ex-dividend date is Tuesday, August 26th. Johnson & Johnson's payout ratio is currently 55.61%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.